Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Grace Therapeutics announced its fiscal year 2026 financial results and business updates, focusing on the planned NDA resubmission for GTx-104 following a Complete Response Letter from the FDA citing Chemistry, Manufacturing, and Controls issues. The company is preparing for a Type A meeting with the FDA to clarify the path forward and continues pr…